Wistuba II - Search Results

1

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ. Martínez-Terroba E, et al. Among authors: wistuba ii. J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20. J Pathol. 2018. PMID: 29756233 Free PMC article.

2

Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis.

Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Huang J, et al. Ann Diagn Pathol. 2001 Dec;5(6):321-9. doi: 10.1053/adpa.2001.29338. Ann Diagn Pathol. 2001. PMID: 11745069

3

Clonality of combined tumors.

Huang J, Behrens C, Wistuba II, Gazdar AF, Jagirdar J. Huang J, et al. Among authors: wistuba ii. Arch Pathol Lab Med. 2002 Apr;126(4):437-41. doi: 10.5858/2002-126-0437-COCT. Arch Pathol Lab Med. 2002. PMID: 11900568 Free article.

4

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

Prudkin L, Wistuba II. Prudkin L, et al. Among authors: wistuba ii. Ann Diagn Pathol. 2006 Oct;10(5):306-15. doi: 10.1016/j.anndiagpath.2006.06.011. Ann Diagn Pathol. 2006. PMID: 16979526 Review.

5

Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.

Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Tang X, et al. Among authors: wistuba ii. Cancer. 2006 Dec 1;107(11):2637-46. doi: 10.1002/cncr.22315. Cancer. 2006. PMID: 17078054 Free article.

6

Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry.

Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Shen J, et al. Among authors: wistuba ii. Cancer Res. 2006 Dec 1;66(23):11194-206. doi: 10.1158/0008-5472.CAN-04-1444. Cancer Res. 2006. PMID: 17145864

7

Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin.

Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. Jin Q, et al. Among authors: wistuba ii. Cancer Res. 2007 Dec 15;67(24):11630-9. doi: 10.1158/0008-5472.CAN-07-2401. Cancer Res. 2007. PMID: 18089792

8

Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.

Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II. Prudkin L, et al. Among authors: wistuba ii. Clin Cancer Res. 2008 Jan 1;14(1):41-7. doi: 10.1158/1078-0432.CCR-07-1252. Clin Cancer Res. 2008. PMID: 18172250 Free PMC article.

9

Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer.

Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Behrens C, et al. Among authors: wistuba ii. Clin Cancer Res. 2008 Oct 1;14(19):6014-22. doi: 10.1158/1078-0432.CCR-08-0167. Clin Cancer Res. 2008. PMID: 18829480 Free PMC article.

10

Data driven semantic integration of translational lung cancer research at MDAnderson Cancer Center.

Deus HF, Stanislaus R, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Almeida JS. Deus HF, et al. Among authors: wistuba ii. AMIA Annu Symp Proc. 2008 Nov 6:927. AMIA Annu Symp Proc. 2008. PMID: 18999102

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

730 results

Search Page

Filters